Xenetic Biosciences, Inc. (XBIO)

Advancing Innovative Immune-Oncology Technologies

Xenetic Biosciences is a biopharmaceutical company focused on advancing proprietary technology platforms across multiple high-value cancer indications.

More About Us

Combating Disease Through Innovative Therapies

Product Pipeline

Platforms

DNase

Oncology platform aimed at improving immunotherapies by targeting Neutrophil Extracellular Traps (NETs)

DNase Platform

Personalized CAR T platform targeting cancers with a patient- and tumor-specific approach.

XCART Platform

Transformative Technologies

Our proprietary and patented technologies are being utilized to create life-changing therapies.

Our Novel Technologies

Latest News

Jan 17, 2023

Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy

Jan 05, 2023

Xenetic Biosciences, Inc. to Present at the Virtual Investor 2023 Companies to Watch Event

Stock Information • View Detailed Stock Information

Nasdaq: XBIO Xenetic Biosciences, Inc.

Price

Change

Volume

Day Range

52 Week Range

Investor Presentation

View Investor Presentation

Get Email Alerts

Stay informed about our latest news and updates